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 PTH(1-34) (Teriparatide) is an anabolic agent used in
treatment of osteoporosis. It promotes bone formation
and reduces the risk of vertebral and some non-
vertebral fractures.
 The route of administration by daily subcutaneous (sc)
injection can cause problems in certain patients. A new
oral delivery system for human PTH(1-34) has been
developed as a possible treatment option.
 Galitzer et al. first presented pre-clinical data (ASBMR
2012, MO0402) and first-in-human results (ASBMR
2013, FR0378) on safety, tolerability and absorption
dynamics of oral PTH(1-34) in various dosages.
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 A single-center, double blinded, triple crossover study was designed to compare the 1.8 mg optimal dose of
oral PTH(1-34) against standard dosage of teriparatide injection and oral placebo.
Sample analysis
Methods
 The study was conducted following and in accordance with the Hadassah Medical Center ethical approval
committee.
 12 healthy volunteers (6m/6f), 18-50y, received three treatments: single subcutaneous injection of 20µg
FORTEO®, 1.8 mg oral PTH(1-34), or placebo.
 Blood samples were collected at time 0, 10, 15, 20, 30, 45, 60, 75, 90, 120, 180, 240, 300 minute post dose.
 Plasma concentration of PTH(1-34) (IDS, Tyne and Wear, UK) and cyclic adenosine 3’,5’monophosphate
(cAMP) were measured on all samples.
 All 12 subjects completed the study, no serious
adverse events (SAE) were reported. Frequency
of AEs were moderate.
 Serum adjusted calcium in all subjects
remained within normal limits throughout the
studies.
 All 12 subjects on oral PTH(1-34) showed rapid,
post dose increase then decrease of PTH(1-34),
from baseline mean (±SD) of 5.9 (1.8) pg/mL to
peak mean of 185.3 (±128.8) pg/mL.
 PK profiles of oral PTH(1-34) showed Cmax
(pg/mL), Tmax (mins), AUC0-last of 238.3 (110.8),
17.5 (5.4) and 6161.7 (2726.7), respectively;
whereas sc group showed mean Cmax (pg/mL),
Tmax (mins), AUC0-last of 172.3 (55.7), 20.8 (8.7)
and 13965.9 (2984.8), respectively.
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Figure 3: Pharmacokinetic profile showing changes in plasma 
PTH(1-34) levels in response to treatments.
One-way ANOVA analysis showed no significant difference in 
Cmax value achieved between oral PTH(1-34) and sc treatment. 
Plasma PTH (1-34) concentration declined more rapidly after oral 
treatment. Significant difference (p<0.05) in plasma PTH(1-34) 
was observed from placebo group 20 minutes post treatment.
 PK profiles showed that a single oral dose of 1.8 mg PTH(1-34) is rapidly absorbed, and there is no significant
difference in Cmax and Tmax when compared with 20µg of Forteo injection.
 A significant difference in the rate of plasma clearance and AUC0-last value was observed between oral and sc
groups. These differing profiles and modality of administration of PTH(1-34) could offer unique advantages in
the treatment of calcium and metabolic bone disorders.
 Linear 4-1000 pg/mL
 Intra-assay imprecision: mean 11.7 pg/mL SD
±0.82, CV 5.4%, 46.7 pg/mL SD ±2.52, CV= 5.4%.
 Inter-assay imprecision: mean 18.5 pg/mL SD
±0.78, CV 4.2%, 46.7 pg/mL, SD ±3.2, CV= 7.0%.
 Negative Ion mode
 13C5-cAMP as internal standard.
 cAMP m/z transition 328 > 134
Figure 1: Effects of teriparatide, 
glucocorticoids and bisphospohates on 
bone cells1
Figure 4: Pharmacokinetic profile showing changes in plasma 
cyclic AMP levels in response to treatments.
IDS iSYS automated immunoassay Ab Sciex API 4000 LC-MS/MS system
PTH(1-34)
Cyclic Adenosine 3’ 5’ 
Monophosphoric acid (cAMP)
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 A transient increase in plasma cAMP was
observed in all subjects in response to PTH(1-
34) treatments. Although the increase is less
apparent in oral than sc both showed a similar
PK profile and a significant difference in plasma
concentration (p<0.05) compared to placebo
group 20 minutes post treatment.
 Increase in cAMP is indicative of PTH bio-
activity, suggesting that the administered
peptide is pharmacologically active and not
degraded during GI transport.
Figure 2: Top: Typical calibration 
curve of concentration range 
from 0 - 240 nmol/L. 
Below: chromatogram showing 
of plasma cAMP.
